Production, Quality Control and Biological Evaluation of 90Y-EDTMP in Rats

Adeli, R; Ghannadi Maragheh, M; Shamsaei Zafarghandi, M; Bahrami Samani, A; Salimi, B

Document Type : Research Paper

Authors

Abstract

Pain palliation of bone metastases is one of the perspectives of medical science. Among the different modalities, the use of radionuclides is a well-established approach. One of these radionuclides is Yttrium-90 (⁹⁰Y) associated with chemical component EDTMP. One method for production of ⁹⁰Y is neutron activation of ⁸⁹Y. This radionuclide is a pure beta emitter with a high energy and appropriate half life and has been considered for medical usages in nuclear medicine. In this research ⁹⁰Y has been produced by irradiation of Y₂O₃ powder and by the addition of EDTMP ligand, the ⁹⁰Y-EDTMP complex has been achieved at ambient temperature. Radiochemical purity was investigated by ITLC method and radionuclidic purity by liquid scintillation counting. The radiopharmaceutical biodistributions were performed in different rat organs.

Highlights

References:

1. Aldo N .Serafani, “Therapy of metastatic bone pain,” J. Nucl. Med. 42 (6), 895- 906 (2001).

2. “Criteria for palliation of bone metastases- Clinical Applications,” IAEA-TECDOC-1549 (2007).

3. Yang Zhi, Jin Xiaohai, Yu Haibin, Bai Shouzhen (Institute of Atomic Energy, Beijing 102413), “Preparation of ⁹⁰Y-EDTMP for bone tomor treatment,” J. Isotopes 5 (2): 72 (1992).

4. Sharmile Banerjee, “¹⁷⁷Lu-DOTMP, ¹⁵³Sm-DOTMP, ¹⁷⁵Yb-EDTMP and^186/188Re-CTMP: “Novel agent for bone pain pallation and their comparison With ¹⁵³Sm-EDTMP,” Founder’s Day Special Issue (2005).

5. J. Kutzer, W. Dahnert, T. Schreyer, W. Grimm, Brod Kh, M. Becher, “Treatment of pain from bone metastase with 90Y,” Nuklearmedizin 20, 229-235 (1981).

6. M. Khalid, A. Mushtaq, “Preparation and in vitro stability of (n,γ) Yttrium-90 Hydroxyapatite,” Applied Radiation and Isotopes 62, 587-590 (2005).

7. F. Rosch and co-workers, “Radiation doses of Yttrium-90 citrate and Yttrium-90 EDTMP as determined via analogous Yttrium-86 complexes and positron emission tomography,” Eur. J. Nucl. Med, 23:958–966 (1996).

8. A.A. Keeling, A.T.M. Vaughan, R.P. Beaney, “Yttrium-90-EDTMP: A radio therapeutic agent in the treatment of leukaemies,” Br. J. Cancer 60, 74-78 (1989).

Keywords

References

References:
1. 1. Aldo N .Serafani, “Therapy of metastatic bone pain,” J. Nucl. Med. 42 (6), 895- 906 (2001).
1. 2. “Criteria for palliation of bone metastases- Clinical Applications,” IAEA-TECDOC-1549 (2007).
1. 3. Yang Zhi, Jin Xiaohai, Yu Haibin, Bai Shouzhen (Institute of Atomic Energy, Beijing 102413), “Preparation of ⁹⁰Y-EDTMP for bone tomor treatment,” J. Isotopes 5 (2): 72 (1992).
1. 4. Sharmile Banerjee, “¹⁷⁷Lu-DOTMP, ¹⁵³Sm-DOTMP, ¹⁷⁵Yb-EDTMP and^186/188Re-CTMP: “Novel agent for bone pain pallation and their comparison With ¹⁵³Sm-EDTMP,” Founder’s Day Special Issue (2005).
1. 5. J. Kutzer, W. Dahnert, T. Schreyer, W. Grimm, Brod Kh, M. Becher, “Treatment of pain from bone metastase with 90Y,” Nuklearmedizin 20, 229-235 (1981).
1. 6. M. Khalid, A. Mushtaq, “Preparation and in vitro stability of (n,γ) Yttrium-90 Hydroxyapatite,” Applied Radiation and Isotopes 62, 587-590 (2005).
1. 7. F. Rosch and co-workers, “Radiation doses of Yttrium-90 citrate and Yttrium-90 EDTMP as determined via analogous Yttrium-86 complexes and positron emission tomography,” Eur. J. Nucl. Med, 23:958–966 (1996).
1. 8. A.A. Keeling, A.T.M. Vaughan, R.P. Beaney, “Yttrium-90-EDTMP: A radio therapeutic agent in the treatment of leukaemies,” Br. J. Cancer 60, 74-78 (1989).

Journal of Nuclear Science, Engineering and Technology (JONSAT)

Production, Quality Control and Biological Evaluation of 90Y-EDTMP in Rats

References

References

Volume 31, Issue 2 - Serial Number 52
August 2010
Pages 40-43

Production, Quality Control and Biological Evaluation of 90Y-EDTMP in Rats

References

References

Volume 31, Issue 2 - Serial Number 52August 2010Pages 40-43

Volume 31, Issue 2 - Serial Number 52
August 2010
Pages 40-43